Degenerative disc disease

More than the Eye Can See: Hospital for Special Surgery First in NYS to Use Augmented Reality Guidance in Spine Surgery

Retrieved on: 
星期三, 十二月 7, 2022
Magnet, Laboratory, Therapy, Hospital, Percussion section, Physician, HSS, Long Island, MD, AR, Degenerative disc disease, Spine, Infection, Anatomy, Skin, American Nurses Credentialing Center, Health, Weill Cornell Medicine, Research, Data collection, Hospital for Special Surgery, Element, The Hospital, FDA, 3D, News, Surgeon, Rheumatology, Multimedia, Safety, Education, U.S. News & World Report, Spinal stenosis, Elective surgery, Nursing, Male, Organization, Medical imaging, Dentistry, Newsweek

NEW YORK, Dec. 7, 2022 /PRNewswire/ -- An orthopedic surgeon at Hospital for Special Surgery (HSS) has performed the first augmented reality-guided spine surgery in New York State.

Key Points: 
  • NEW YORK, Dec. 7, 2022 /PRNewswire/ -- An orthopedic surgeon at Hospital for Special Surgery (HSS) has performed the first augmented reality-guided spine surgery in New York State.
  • Augmented reality refers to digital information that is superimposed on a user's view of the physical environment, providing images that can't be seen with the naked eye.
  • AR navigation in spine surgery superimposes 3D images of a patient's anatomy onto the surgeon's view of the operative field.
  • Critical elements include a preoperative CT scan of the patient's spine, which is used to plan and perform the surgery, and an augmented reality headset worn during the procedure.

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

Retrieved on: 
星期二, 十一月 29, 2022
Stem cell, Degenerative disc disease, Food, Conference, Cell, Bone marrow, Risk, Pain, Patient, Glucose, Diabetes, Therapy, Food and Drug Administration, BAT, Human, Animal, B cell, Obesity, Pharmaceutical industry

MELVILLE N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

Key Points: 
  • MELVILLE N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City.
  • The RHK Capital Disruptive Growth Conference will feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies to meet with seasoned institutional investors, accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients.
  • To learn more and submit a registration request, visit http://disruptnyc.com/
    BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
  • Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

Retrieved on: 
星期日, 十一月 27, 2022
Spinal disc herniation, Spondylolisthesis, Degenerative disc disease, PTH, Pain, SIX Swiss Exchange, Spine, Magneto, Movement, Spinal fusion, Back pain, Parathyroid hormone, Kuros, Human, Surgeon, Safety, Lithium, Pharmaceutical industry

The safety & efficacy of Fibrin-PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.

Key Points: 
  • The safety & efficacy of Fibrin-PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.
  • Lumbar fusion surgery is designed to create solid bone between adjoining vertebrae of the spine, eliminating any movement between the bones.
  • Spinal fusion may be recommended for conditions such as spondylolisthesis, degenerative disc disease or recurrent disc herniations.
  • Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain.

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Retrieved on: 
星期三, 十一月 16, 2022
Stem cell, Degenerative disc disease, Food, Conference, Bone marrow, Cell, Risk, Pain, Patient, Glucose, Diabetes, Security (finance), Food and Drug Administration Amendments Act of 2007, BAT, Human, Animal, B cell, Form 10-K, Obesity, Pharmaceutical industry

Melville, NY., Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq:BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies,today announced that it will participate on December 5-6, 2022 at the RHK Capital Disruptive Growth Conference in New York City.

Key Points: 
  • Melville, NY., Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq:BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies,today announced that it will participate on December 5-6, 2022 at the RHK Capital Disruptive Growth Conference in New York City.
  • He will provide an update onthe Company's expanded pipeline and near-term catalysts of itsongoing Phase 2 clinical trial targeting chronic lumbar disc disease.
  • Further information on this conference can be found below:
    December 5 -6 2022@ Reed Smith LLP - New York, NY
    BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
  • The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

SmartTRAK Advances Medtech Market Insights Platform; Announces New Modules for Wound Care and Orthopedic/Spine Injectables

Retrieved on: 
星期二, 十一月 8, 2022
Linda, Health Data Insight, Enabling technology, Wound, Wilford Hall Ambulatory Surgical Center, CMS, General manager, Degenerative disc disease, Software as a service, Regenerative medicine, Medtech, Intelligence, Knee, ASC, OA, Elective surgery, Osteoarthritis, Solution, Wound healing, Pulse, History, Strategic planning, Pharmaceutical industry, Retail, Medical device, Debridement, Orthopedic surgery

IRVINE, Calif., Nov. 8, 2022 /PRNewswire-PRWeb/ -- SmartTRAK, the leading global Medtech business and market insights platform in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the expansion of its solutions portfolio focused on new market coverage for Wound Debridement and Injectables for spinal disc degeneration and osteoarthritis (OA) of the knee.

Key Points: 
  • SmartTRAK is an Insights-as-a-Service platform that equips customers with real-time, accurate market, company and product insights from hundreds of carefully curated data sources.
  • Wound Debridement , a newly covered segment offered on the SmartTRAK platform, is foundational to wound healing and the success of every advanced wound care product.
  • The Debridement and Injectables market expansions are examples of how SmartTRAK helps our customers stay on the forefront of market advancements."
  • SmartTRAK is the Medtech industry's only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets.

Centinel Spine Announces 100th Procedure with prodisc® C Vivo Cervical Total Disc Replacement Product

Retrieved on: 
星期四, 十月 27, 2022
LLC, Degenerative disc disease, Disarticulation, Pain, Spine, Solution, Surgeon, Industry, Technology, WEST, Culture, Patient, Company, TDR, Anatomy, Disability, X-ray, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Vivo, CORE, Motion, Medical device, Birth control, Dentistry

The 100th procedure milestone was achieved quickly following the announcement of the first U.S. prodisc C Vivo implantation on Sept. 7.

Key Points: 
  • The 100th procedure milestone was achieved quickly following the announcement of the first U.S. prodisc C Vivo implantation on Sept. 7.
  • The prodisc C Vivo device incorporates prodisc CORE technology used in over 225,000 implantations worldwide.
  • WEST CHESTER, Pa., Oct. 27, 2022 /PRNewswire/ --Centinel Spine, LLC, ("the Company") a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the 100th completed procedure in the United States with its prodisc C Vivo Cervical Total Disc Replacement (TDR) product.
  • This milestone was achieved quickly after the Company announced the first U.S. implantation of the prodisc C Vivo on Sept. 7.

Bone Biologics CEO Issues Letter to Stockholders

Retrieved on: 
星期二, 十月 25, 2022
General Health, Health, Surgery, Other Health, Sheep, Spinal stenosis, Caregiver, Cell bank, Technology, Deformity, NB1, Bharat Immunologicals and Biologicals Corporation, Review, B cell, Technology transfer, CGMP, NASDAQ, Patient, Osteoporosis, Spondylolisthesis, Allotransplantation, Oswestry Disability Index, Degenerative disc disease, UCLA, Publication, Trial of the century, Spinal fusion, CDMO, Trauma, Safety, Letter, DBM, Clinical trial, Environment, Gold standard, MTF, Human, Vaccine, Pharmaceutical industry, Fine chemical, Medical device

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.
  • This potential lies in its ability to provide rapid, specific and guided control over bone regeneration.
  • This is the market Bone Biologics intends to address.
  • We believe our effort will be well-rewarded not only by patients, but also by caregivers and Bone Biologics stockholders.

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

Retrieved on: 
星期四, 十月 20, 2022
U.S. Securities and Exchange Commission, Securities Act of 1933, Risk, Glucose, B cell, BAT, Animal, Stem cell, NASDAQ, Patient, Human, Cell, Security (finance), Bone marrow, Degenerative disc disease, Private Securities Litigation Reform Act, Form 10-K, Company, Obesity, Friends, Pain, Adult, Securities Exchange Act of 1934, Safety, Lists of diseases, Diabetes, Metabolism, GLOBE, Radio, Pharmaceutical industry

MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company or BioRestorative) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk Radio Show to discuss the Companys progress and updates on its clinical development pipeline.

Key Points: 
  • MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company or BioRestorative) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk Radio Show to discuss the Companys progress and updates on its clinical development pipeline.
  • The radio show, which airs Sundays7-8 pmon AM1170/FM96.1, is hosted byFamela Ramosalong with "friends"Kalina O'Connor and Wais Kaihani.
  • We are excited to have the opportunity to be guests of Famela and Friends, said Lance Alstodt, the Companys CEO.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

Accelus Announces Global Expansion of its FlareHawk Interbody Fusion System

Retrieved on: 
星期二, 十月 18, 2022
Adoption, International, Growth, Robotics, Part, PALM, Patient, Surgeon, Entrepreneurship, History, Degenerative disc disease, Technology, Certification, Spine, BEACH, Canadian International Council, Economics, MIS, GLOBE, CE, FDA, DDD, DOI, Dentistry, Medical device

The FlareHawk System was recently cleared for use in Italy, Taiwan, Portugal and Colombia, bringing the total number of countries where FlareHawk can be used to 21.

Key Points: 
  • The FlareHawk System was recently cleared for use in Italy, Taiwan, Portugal and Colombia, bringing the total number of countries where FlareHawk can be used to 21.
  • Accelus is proud to have partnered with some of the very best spine-focused distributors to bring our flagship FlareHawk expandable interbody device to surgeons and their patients globally, said Jose Calleja, Executive Vice President of International for Accelus.
  • The FlareHawk Expandable Lumbar Interbody Fusion Device received FDA 510(k) clearance in August 2016 and CE mark certification in May 2021.
  • Current Concepts of Contemporary Expandable Lumbar Interbody Fusion Cage Designs, Part 2: Feasibility Assessment of an Endplate Conforming Bidirectional Expandable Interbody Cage.

Interbody Fusion Cage Global Market Report 2022: Worldwide Increases in Spinal Cord Injuries Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期五, 十月 21, 2022
Surgery, Health, Medical Devices, Aurora, Inorganic polymer, Adoption, Metal, Titanium, Growth, CAGR, Johnson & Johnson, Decompression, Hospital, Spine, Arthrodesis, Accident, Spinal fusion, Degenerative disc disease, Medtronic, Clifton Springs Hospital & Clinic, Spinal cord injury, NuVasive, Trapping

Interbody fusion cage is an artificial medical device, which is utilized in spinal fusion procedures to maintain foraminal height and decompression.

Key Points: 
  • Interbody fusion cage is an artificial medical device, which is utilized in spinal fusion procedures to maintain foraminal height and decompression.
  • The interbody fusion cage is a large, hollow cylinder made up of metals such as titanium, carbon fiber, or allograft femur.
  • However, high cost associated with spinal fusion surgeries and dearth of skilled professionals are anticipated to impede the growth of interbody fusion cage market.
  • By product type, the market is segregated into lumbar cage, cervical cage, thoraco-lumbar cage, and thoracic cage.